Skip to main content
Back
Watch Compare

Lineage Cell Therapeutics, Inc.

Data quality: 100%
LCTX
NYSE Manufacturing Chemicals
$1.51
▼ $0.04 (-2.27%)
Mkt Cap: 374.88 M
Price
$1.51
Mkt Cap
374.88 M
Day Range
$1.49 — $1.56
52-Week Range
$0.38 — $2.09
Volume
616,244
Open $1.52
50D / 200D Avg
$1.68
10.19% below
50D / 200D Avg
$1.51
0.28% below

Quick Summary

Key Takeaways

Revenue grew 35.32% annually over 5 years — strong growth
Negative free cash flow of -19.44 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 17.92%
Capital efficient — spends only 3.59% of revenue on capex

Growth

Revenue Growth (5Y)
35.32%
Above sector avg (1.82%)
Revenue (1Y)53.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-180.43%
Below sector avg (-53.47%)
ROIC-36.09%
Net Margin-436.47%
Op. Margin-251.57%

Safety

Debt / Equity
N/A
Current Ratio4.50
Interest CoverageN/A

Valuation

PE (TTM)
-5.90
Below sector avg (-1.47)
P/B Ratio17.01
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -5.9 -1.5
P/B 17.0 1.6
ROE % -180.4 -53.5
Net Margin % -436.5 -41.5
Rev Growth 5Y % 35.3 1.8
D/E — 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.08% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 53.24% Revenue Growth (3Y) 27.56%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 35.32% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14.56 M Net Income (TTM) -63.53 M
ROE -180.43% ROA -70.42%
Gross Margin N/A Operating Margin -251.57%
Net Margin -436.47% Free Cash Flow (TTM) -19.44 M
ROIC -36.09% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.50
Interest Coverage N/A Asset Turnover 0.16
Working Capital 32.88 M Tangible Book Value -20.33 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5.90 Forward P/E N/A
P/B Ratio 17.01 P/S Ratio 25.75
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -5.19%
Market Cap 374.88 M Enterprise Value 334.41 M
Per Share
EPS (Diluted TTM) -0.28 Revenue / Share 0.06
FCF / Share -0.08 OCF / Share -0.08
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3.59% FCF Conversion 30.60%
SBC-Adj. FCF -24.43 M Growth Momentum 17.92

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.56 M 9.50 M 8.95 M 14.70 M 4.34 M
Net Income -63.53 M -18.61 M -21.49 M -26.27 M -43.02 M
EPS (Diluted) -0.28 -0.09 -0.12 — —
Gross Profit — — 8.27 M 13.98 M 2.92 M
Operating Income -36.62 M -21.48 M -24.73 M -22.52 M -49.21 M
EBITDA — — — — —
R&D Expenses 17.73 M 12.47 M 15.71 M 13.99 M 33.91 M
SG&A Expenses — — — — —
D&A 699,000.0 587,000.0 562,000.0 582,000.0 663,000.0
Interest Expense — — — 829,000.0 2,000.0
Income Tax -5.28 M 0.0 -1.80 M 541,000.0 -1.24 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 112.58 M 113.22 M 101.02 M 123.66 M 174.55 M
Total Liabilities 69.24 M 36.21 M 39.00 M 51.73 M 83.65 M
Shareholders' Equity 44.55 M 78.38 M 63.42 M 73.34 M 92.22 M
Total Debt — — — — —
Cash & Equivalents 40.79 M 45.79 M 35.44 M 11.36 M 55.74 M
Current Assets 59.16 M 51.00 M 38.44 M 60.00 M 111.55 M
Current Liabilities 11.37 M 13.98 M 17.96 M 18.98 M 47.12 M